Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer
- Tuesday, August 11, 2020, 7:12
- Environment
- Add a comment
WOODCLIFF LAKE, N.J., Aug. 11, 2020 /PRNewswire/ — Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, comparing two starting…
About the Author
adminasapcorp has written 41558 stories on this site.